摘要
In neuroendocrine tumors(NETs),liver metastases(LM)represent the most crucial prognostic factor,irrespective of the primary tumor site.At diagnosis,about 65-95%of gastroenteropancreatic neuroendocrine tumors(GEP-NETs)show hepatic metastasis.Management strategies of LM are heterogeneous and range from systemic therapy to liver-directed procedures.The type of systemic therapy used is dependent on the grade and proliferation of the tumor and includes somatostatin analogues,interferon,m-Tor and tyrosine kinase inhibitors,and chemotherapy.Angiographic liver-directed techniques,such as transarterial embolization/chemoembolization and selective internal radiation therapy,offer excellent palliation for patients with liver-predominant disease.In highly selected cases,liver transplantation and peptide receptor radionuclide therapy are considered.The relatively low disease incidence and the diversity of presentation have led to a lack of well-conducted randomized controlled trials comparing the efficacy of different treatment options.Experience indicates that surgery is the only treatment that offers potential for cure.For unresectable lesions,the absence of data from rigorous trials limits the validity of many publications that detail management.In this review we will discuss the existing approaches for hepatic metastases from GEP-NETs.
